C9146 HCPCS Level II code: Injection, mirvetuximab soravtansine-gynx, 1 mg
CMS terminated C9146: its last date of service was Jun 30, 2023. It stays here for looking up older claims; newer services need a current code.
Official description
C9146Injection, mirvetuximab soravtansine-gynx, 1 mg
Short description: Inj, elahere, 1 mg
HCPCS · United States
Medicare details
The indicators CMS publishes with C9146 in its October 2026 file. They describe Medicare’s handling, not another payer’s.
- Medicare coverage
- Special coverage instructions apply
- Medicare pricing
- Statute
- Type of service
- Medical care; Ambulatory surgical center (facility usage for surgical services)
- BETOS category
- Other drugs
- Coverage statute
- 1833(t)
- Added
- Apr 1, 2023
- Terminated after
- Jun 30, 2023
Where C9146 sits
- 1C codesOutpatient prospective payment system
- 2Terminated C9146Injection, mirvetuximab soravtansine-gynx, 1 mg
Source and release
- Data release
- HCPCS Level II · October 2026
- Effective date
- Oct 1, 2026
- Publisher
- CMS
This page is built from the HCPCS Level II catalog that Vero Codes reads when it suggests codes: Centers for Medicare & Medicaid Services’s October 2026 release, imported from the publisher’s file and checked against it. The description, notes and structured data come from the same record.
Frequently asked questions
Is HCPCS code C9146 still valid?
No. CMS terminated C9146; its last date of service was Jun 30, 2023. It is listed for looking up services from before then. Use a current code for newer services.
Does Medicare cover C9146?
CMS lists C9146’s Medicare coverage as “Special coverage instructions apply” and its pricing as “Statute”. Coverage and payment still depend on the patient, the setting, the documentation and the payer.
Which HCPCS Level II release does this page use?
It uses CMS’s October 2026 release, in effect from Oct 1, 2026 to Dec 31, 2026. It is a reference: confirm the code against the current list and the payer’s rules before you submit it.
Codes beside C9146
All C codesC9140Injection, factor viii (antihemophilic factor, recombinant) (afstyla), 1 i.u.C9141Injection, factor viii, (antihemophilic factor, recombinant), pegylated-aucl (jivi), 1 i.u.C9142Injection, bevacizumab-maly, biosimilar, (alymsys), 10 mgC9143Cocaine hydrochloride nasal solution (numbrino), 1 mgC9144Injection, bupivacaine (posimir), 1 mgC9145Injection, aprepitant, (aponvie), 1 mgC9147Injection, tremelimumab-actl, 1 mgC9148Injection, teclistamab-cqyv, 0.5 mgC9149Injection, teplizumab-mzwv, 5 mcgC9150Xenon xe-129 hyperpolarized gas, diagnostic, per study doseC9151Injection, pegcetacoplan, 1 mgC9152Injection, aripiprazole, (abilify asimtufii), 1 mg